ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

Promising Areas Of Research Listed By NCAB Subcommittee

February 12, 1982

Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer

February 25, 2011

NCI, GW Scientists Report Advances On AIDS Vaccine

May 30, 1986

Monroe Wall, Co-Discoverer Of Taxol, Camptothecin, Dead At 85

July 12, 2002

Facilities Survey To Include All Institutions With $200,000 Or More in NCI Support

October 5, 1984

In Brief: Comprehensive Centers “Jewel In Crown” Of Cancer Program, DeVita Says; Boutwell New NCAB Member

February 18, 1983